Skip to main content
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
What the Next Generation of Cancer Biomarkers May Involve
Video
,
ASCO Highlights
Videos
Sanjiv Agarwala, MD
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Related Items
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024 Vol 17, No 2
ASCO Highlights
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024 Vol 17, No 2
ASCO Highlights
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
By
Patricia Stewart
TOP - July 2022 Vol 15, No 4
Rectal Cancer
,
ASCO Highlights
Ibrutinib Added to Standard-of-Care Therapy Improves Progression-Free Survival in Older Patients with MCL
By
William King
TOP - July 2022 Vol 15, No 4
ASCO Highlights